Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| JATT II Acquisition Corp.JATT · Entity 6799 | Director | April 16, 2026 | April 17, 2026 |
| JATT III Acquisition CorpJTTT · Entity 6795 | Director | August 25, 2026 | August 25, 2026 |
| Zura Bio LtdZURA · Entity 5413 | Chief Financial Officer | May 08, 2025 | May 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
JATT II Acquisition Corp.
Report date April 16, 2026 · Filed April 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | IndirectSee footnote | 25,000 |
Reported balance
Holding disclosure · report date 2026-04-16 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 25,000 F1: For his services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, JATT Ventures II L.P. |
Filing footnotes · ownership attribution and instrument terms
F1: For his services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, JATT Ventures II L.P.
JATT III Acquisition Corp
Report date August 25, 2026 · Filed August 25, 2026
This filing explicitly reported no securities owned.
Zura Bio Ltd
Report date May 08, 2025 · Filed May 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.26 · Expires 2035-05-08 | Direct | 303,100 |
Reported balance
After 2025-05-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-08 · Grant · Acquired 303,100 · Balance 303,100 F1: One fourth (1/4th) of the shares subject to the option award shall vest on February 27, 2026, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One fourth (1/4th) of the shares subject to the option award shall vest on February 27, 2026, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2025 Filed May 12, 2025 20:15 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 303,100 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001415889-25-012656 · form4-05122025_040525.xml · derivative · entry 1 Badial Verender S. · CIK 0001870327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,100 Underlying: Class A Ordinary Shares · 303,100 shares Expires 2035-05-08 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on February 27, 2026, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| August 23, 2024 Filed Feb 14, 2025 21:26 UTC | Zura Bio Ltd ZURA · Entity 5413 | Disposition to issuerWarrants · Derivative | 420,519 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-004111 · form5-02142025_090206.xml · derivative · entry 5 Badial Verender S. · CIK 0001870327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 420,519 shares Expires 2028-03-20 F2 · kind: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F2 · price: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. Read SEC document |
| August 23, 2024 Filed Feb 14, 2025 21:26 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantClass A Ordinary Shares | 126,155 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004111 · form5-02142025_090206.xml · nonDerivative · entry 3 Badial Verender S. · CIK 0001870327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,519 F2 · kind: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. F2 · price: The reported warrants were exchanged for Class A Ordinary Shares ("Ordinary Shares") pursuant to an exchange offer from the Issuer. Each warrant holder whose warrants were exchanged pursuant to the exchange offer received 0.30 Ordinary Shares for each warrant tendered by such holder and exchanged. No fractional Ordinary Shares were issued pursuant to the exchange offer, with fractional shares paid in cash (without interest). The foregoing description of the exchange offer does not purport to be complete and is subject to, and qualified in its entirety by, the S-4 of the Issuer filed on July 12, 2024, as amended, which is incorporated herein by reference. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 22:10 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 420,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001415889-24-017862 · form4-06212024_060610.xml · derivative · entry 1 Badial Verender S. · CIK 0001870327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 420,000 Underlying: Class A Ordinary Shares · 420,000 shares Expires 2034-06-18 F1 · derivative.exercise_date: One fourth (1/4th) of the shares subject to the option award shall vest on June 18, 2025, and one twelfth (1/12th) of the remaining shares subject to the option award shall vest in equal quarterly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 28, 2023 Filed Feb 14, 2025 21:26 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherWarrants · Derivative | 420,519 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001415889-25-004111 · form5-02142025_090206.xml · derivative · entry 4 Badial Verender S. · CIK 0001870327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 420,519 shares Expires 2028-03-20 F3 · kind: The warrants were distributed by JATT to the Reporting Person for no additional consideration. F3 · price: The warrants were distributed by JATT to the Reporting Person for no additional consideration. Read SEC document |
| September 28, 2023 Filed Feb 14, 2025 21:26 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherClass A Ordinary Shares | 355,880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004111 · form5-02142025_090206.xml · nonDerivative · entry 2 Badial Verender S. · CIK 0001870327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,519 F1 · kind: The Class A ordinary shares were distributed by JATT Ventures L.P. ("JATT") to the Reporting Person for no additional consideration. F1 · price: The Class A ordinary shares were distributed by JATT Ventures L.P. ("JATT") to the Reporting Person for no additional consideration. Read SEC document |
| September 22, 2023 Filed Feb 14, 2025 21:26 UTC | Zura Bio Ltd ZURA · Entity 5413 | OtherClass A Ordinary Shares | 35,484 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-004111 · form5-02142025_090206.xml · nonDerivative · entry 1 Badial Verender S. · CIK 0001870327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 517,519 F1 · kind: The Class A ordinary shares were distributed by JATT Ventures L.P. ("JATT") to the Reporting Person for no additional consideration. F1 · price: The Class A ordinary shares were distributed by JATT Ventures L.P. ("JATT") to the Reporting Person for no additional consideration. Read SEC document |
| May 18, 2023 Filed May 23, 2023 01:15 UTC | Zura Bio Ltd ZURA · Entity 5413 | GrantEmployee Share Option (Right to Buy) · Derivative | 575,000 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001104659-23-063311 · tm2316481-1_4seq1.xml · derivative · entry 1 Badial Verender S. · CIK 0001870327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,000 Underlying: Class A Ordinary Shares · 575,000 shares Expires 2033-05-18 F1 · derivative.exercise_price: The Employee Share Option is a nil cost option granted under the Issuer's 2023 Equity Incentive Plan and the applicable UK Subplan. F2 · derivative.exercise_date: 25% of the option shall become exercisable on May 18, 2024 and a further 2.083% of it shall become exercisable at the end of each month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.